WO2006055659A3 - Fixed dose combination op dutasteride and tamsulosin - Google Patents

Fixed dose combination op dutasteride and tamsulosin Download PDF

Info

Publication number
WO2006055659A3
WO2006055659A3 PCT/US2005/041580 US2005041580W WO2006055659A3 WO 2006055659 A3 WO2006055659 A3 WO 2006055659A3 US 2005041580 W US2005041580 W US 2005041580W WO 2006055659 A3 WO2006055659 A3 WO 2006055659A3
Authority
WO
WIPO (PCT)
Prior art keywords
fixed dose
dutasteride
tamsulosin
dose combination
alpha
Prior art date
Application number
PCT/US2005/041580
Other languages
French (fr)
Other versions
WO2006055659A2 (en
Inventor
Samuel Bruce Balik
Angela Dawn Glendenning
Mickey Lee Wells
Original Assignee
Smithkline Beecham Corp
Samuel Bruce Balik
Angela Dawn Glendenning
Mickey Lee Wells
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Samuel Bruce Balik, Angela Dawn Glendenning, Mickey Lee Wells filed Critical Smithkline Beecham Corp
Publication of WO2006055659A2 publication Critical patent/WO2006055659A2/en
Publication of WO2006055659A3 publication Critical patent/WO2006055659A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Abstract

Pharmaceutical compositions that include a steroid 5-alpha reductase inhibitor in a fixed dose combination with an alpha adrenergic blocker are described.
PCT/US2005/041580 2004-11-15 2005-11-15 Fixed dose combination op dutasteride and tamsulosin WO2006055659A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62799804P 2004-11-15 2004-11-15
US60/627,998 2004-11-15

Publications (2)

Publication Number Publication Date
WO2006055659A2 WO2006055659A2 (en) 2006-05-26
WO2006055659A3 true WO2006055659A3 (en) 2007-03-15

Family

ID=36123125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041580 WO2006055659A2 (en) 2004-11-15 2005-11-15 Fixed dose combination op dutasteride and tamsulosin

Country Status (1)

Country Link
WO (1) WO2006055659A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021891A2 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
US20110244033A1 (en) * 2008-12-09 2011-10-06 Denny Johan Marijn Van Den Heuvel Tamsulosin pellets for fixed dose combination
EP2395975A4 (en) 2009-02-10 2013-05-22 Genepharm India Private Ltd An oral pharmaceutical composition of dutasteride
EP2468262A1 (en) * 2010-12-06 2012-06-27 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising dutasteride
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
US9622981B2 (en) * 2011-11-17 2017-04-18 Mylan Inc. Liquid-filled hard gel capsule pharmaceutical formulations
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
WO2014002015A1 (en) * 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition comprising dutasteride
CN103830201A (en) * 2012-11-20 2014-06-04 重庆医药工业研究院有限责任公司 Dutasteride liquid soft capsules
US20160287524A1 (en) * 2013-03-19 2016-10-06 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
RU2015143891A (en) * 2013-06-21 2017-07-24 Вокхардт Лимитед PHARMACEUTICAL COMPOSITIONS OF TAMSULOSIN OR ITS SALTS
BR102013020508B1 (en) 2013-08-12 2021-01-12 Ems S/A. DOSAGE FORM THAT UNDERSTANDS A 5-ALPHA REDUCTASE STEROID INHIBITOR AND AN ALPHA BLOCKER, PROCESS FOR THE PREPARATION OF A DOSAGE FORM AND USE OF THE DOSAGE FORM
ES2555485T1 (en) 2014-05-26 2016-01-04 Galenicum Health S.L. Pharmaceutical compositions containing an active agent
AU2017233134A1 (en) * 2016-03-16 2018-10-04 Hanmi Pharm. Co., Ltd. Dutasteride- and tamsulosin-containing hard capsule complex and preparation method therefor
RS64882B1 (en) 2018-05-19 2023-12-29 Zim Laboratories Ltd Novel pharmaceutical composition of tamsulosin and dutasteride
CN111759821B (en) * 2020-08-24 2021-10-08 四川奥邦投资有限公司 Dutasteride soft capsule pharmaceutical composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008666A2 (en) * 1997-08-19 1999-02-25 Glaxo Group Limited Pharmaceutical composition comprising an azateroid
WO2001000182A1 (en) * 1999-06-28 2001-01-04 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
WO2003039531A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Modified release tamsulosin tablets
WO2003090753A1 (en) * 2002-04-24 2003-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
WO2005004851A1 (en) * 2003-07-01 2005-01-20 Krka, Tovarna Zdravil, D.D. Novo Mesto Tamsulosin core with a coating of polyvinylpyrrolidone and polyvinylacetate
WO2005053659A1 (en) * 2003-12-03 2005-06-16 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008666A2 (en) * 1997-08-19 1999-02-25 Glaxo Group Limited Pharmaceutical composition comprising an azateroid
WO2001000182A1 (en) * 1999-06-28 2001-01-04 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
WO2003039531A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Modified release tamsulosin tablets
WO2003090753A1 (en) * 2002-04-24 2003-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
WO2005004851A1 (en) * 2003-07-01 2005-01-20 Krka, Tovarna Zdravil, D.D. Novo Mesto Tamsulosin core with a coating of polyvinylpyrrolidone and polyvinylacetate
WO2005053659A1 (en) * 2003-12-03 2005-06-16 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARKIN J ET AL: "DUTASTERIDE PROVIDES SUSTAINED SYMPTOM RELIEF FOLLOWING SHORT TERM COMBINATION TREATMENT WITH TAMSULOSIN", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 167, no. SUPPL 4, 29 May 2002 (2002-05-29), pages 372, XP008019469, ISSN: 0022-5347 *

Also Published As

Publication number Publication date
WO2006055659A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
WO2006055659A3 (en) Fixed dose combination op dutasteride and tamsulosin
TWI317619B (en) Composition for the improvement of liver function, the reduction of serum ethanol level and antioxidant activity enhancement
DOP2019000185A (en) A SOLID PHARMACEUTICAL DOSAGE FORMULATION
IL183102A0 (en) Betulin derivatives and pharmaceutical compositions containing the same
ZA200708544B (en) Nanoparticulate corticosteroid and antihistamine formulations
HK1098368A1 (en) Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid
IL183088A0 (en) Inhibitors of 11-?? hydroxyl steroid dehydrogenase type 1 and methods of using the same
WO2005117872A3 (en) Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
WO2005101540A3 (en) Oled device with short reduction
AU2003228666A1 (en) Lapachone delivery systems, compositions and uses related thereto
EP1718303A4 (en) Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
EP1618487A4 (en) Systems and methods for fragment-based serialization
AU2003266658A1 (en) Text edition device and program
HK1080384A1 (en) Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
IL178775A0 (en) Pharmaceutical compositions for acute glucocorticoid therapy
TW200510002A (en) Solid pharmaceutical preparation
EP1633311A4 (en) Compositions and methods for modulating s-nitrosoglutathione reductase
WO2007095259A3 (en) Antimycotic rhamnolipid compositions and related methods of use
HK1109579A1 (en) Pharmaceutical composition comprising drospirenone and ethynylestradiol
SG116560A1 (en) Mosfet with electrostaic discharge protection structure and method of fabrication.
IL180651A0 (en) Compositions comprising 5-alpha reductase inhibitors, and serms and methods of use thereof
AU2003246143A1 (en) Polypeptide agent for inhibiting sars coronavirus and its derivatives and use thereof
ZA200706785B (en) Use of estrogen receptor-β selective agonists for radiation-or chemotherapy-induced mucosistis and radiation cystitis
TWI372759B (en) A complex comprising mequitazine, a cyclodextrin, and an interaction agent
ZA200610727B (en) Compositions comprising strontium and vitamin D and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05825847

Country of ref document: EP

Kind code of ref document: A2